Business
biOasis to Present at The Global Chinese Financial Forum - Shanghai Conference 2017
biOasis to Present at The Global Chinese Financial Forum - Shanghai Conference 2017.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\nbiOasis to Present at The Global Chinese Financial Forum - Shanghai Conference 2017\n\nbiOasis to Present at The Global Chinese Financial Forum - Shanghai Conference 2017\n\n VANCOUVER, BC--(Marketwired - June 08, 2017) - BIOASIS TECHNOLOGIES INC. (OTCQB: BIOAF) (TSX VENTURE: BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) - Shanghai Conference 2017, in Shanghai, China, on June 22, 2017. biOasis Board Chairman, Rob Hutchison, will attend the conference with Dr. Day. Dr. Day's presentation, \"A Ground-Breaking Platform for the Delivery of Therapeutic Compounds Across the Blood-Brain Barrier,\" will be attended by a wide assortment of private investors, life science companies and investment funds. The GCFF - Shanghai Conference 2017 will be held concurrently with China's largest pharma-focused event, the CPhI China Conference.\"The Chinese pharmaceutical industry is one of the largest in the world with double-digit growth and exceptional opportunities for biOasis,\" said Dr. Mark Day, CEO, biOasis. \"The GCFF - Shanghai Conference 2017 offers biOasis the opportunity to introduce our Transcend Platform to executives and scientists from many of China's largest life science companies and to begin building alliances throughout Asia.\"\"On a personal note, the conference is my first opportunity to publicly express my excitement about biOasis and to discuss our strategies for the Transcend Platform going forward,\" said Dr. Day. \"I have described Transcend as one of the most unique and promising blood-brain barrier technologies of our time. I look forward to meeting my industry colleagues and establishing new ones, placing biOasis in the mix of growth opportunities the Chinese pharmaceutical industry can offer us.\"About TranscendTranscend is biOasis' proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to...